Private Capital Group’s Nektar Therapeutics NKTR Stock Holding History

Private Capital Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Buy	19 +2	+12%	+$126	﹤0.01%	1742
2022 Q1	$1K	Buy	17 +10	+143%	+$1.48K	﹤0.01%	1970
2021 Q4	$1K	Buy	7 +3	+75%	+$651	﹤0.01%	1965
2021 Q3	$1K	Hold	4	–	–	﹤0.01%	2029
2021 Q2	$1K	Hold	4	–	–	﹤0.01%	2000
2021 Q1	$1K	Hold	4	–	–	﹤0.01%	1906
2020 Q4	$1K	Hold	4	–	–	﹤0.01%	1924
2020 Q3	$1K	Buy	+4	New	+$1.26K	﹤0.01%	1870
2020 Q1	–	Sell	-4	Closed	-$1K	–	2079
2019 Q4	$1K	Sell	4 -4	-50%	-$1.16K	﹤0.01%	1826
2019 Q3	$2K	Buy	8 +7	+700%	+$2.57K	﹤0.01%	1910
2019 Q2	$1K	Buy	+1	New	+$501	﹤0.01%	2054
2018 Q4	–	Sell	-1	Closed	-$1K	–	2299
2018 Q3	$1K	Hold	1	–	–	﹤0.01%	2079
2018 Q2	$0	Sell	1 -26	-96%	-$30K	﹤0.01%	2221
2018 Q1	$44K	Hold	27	–	–	0.01%	741
2017 Q4	$24K	Buy	+27	New	+$16K	0.01%	994

Other funds holding NKTR

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Private Capital Group's NKTR Position: Q2 2022 in Review

Private Capital Group increased its Nektar Therapeutics (NKTR) stake by 12% in Q2 2022, buying an estimated $126 and bringing the position to 19 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Private Capital Group first reported a position in NKTR in Q4 2017 and has held it in 15 quarters since. The position peaked at $44K in Q1 2018. 228 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Private Capital Group held 19 shares of Nektar Therapeutics worth $1K as of Q2 2022.
Private Capital Group bought 2 Nektar Therapeutics shares in Q2 2022, an estimated $126.
Nektar Therapeutics made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1742 holding.
Private Capital Group first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 15 quarters since.
Private Capital Group's Nektar Therapeutics position peaked at $44K in Q1 2018.
228 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.